|Articles|April 24, 2017
Cliantha Research Acquires Inflamax Research
Cliantha Research has announced the acquisition of Inflamax Research. Inflamax aims to use its inflammatory disease research and natural allergen Environmental Exposure Chambers (EEC) to assist Cliantha in conducting asthma, allergy, ophthalmology and tobacco research plus specialized pulmonary/respiratory therapeutic studies.Read the full release here
Advertisement
Cliantha Research has announced the acquisition of Inflamax Research. Inflamax aims to use its inflammatory disease research and natural allergen Environmental Exposure Chambers (EEC) to assist Cliantha in conducting asthma, allergy, ophthalmology and tobacco research plus specialized pulmonary/respiratory therapeutic studies.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Breaking the Efficacy Ceiling in IBD and Beyond
2
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
3
ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program
4
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
5